Nucleoside Analog Antiviral
28 drugs across 14 manufacturers|27 Generic,1 Brand
The Nucleoside Analog Antiviral class contains 28 NDCs from 14 manufacturers (27 generic, 1 brand), at an average NADAC of $5.41 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
28
27G / 1B
Manufacturers
14
Avg $5.4118/unit
Avg 7d Change
-1.31%
Across 21 drugs with changes
7d Activity
of 28 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
14 manufacturers producing drugs in this therapeutic class(2 pricing outliers)
and 2 more manufacturers
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Aurobindo Pharma Limited manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Valganciclovir market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Nucleoside Analog Antiviral class?
The Nucleoside Analog Antiviral class contains 28 NDCs from 14 manufacturers — 27 generic and 1 brand product.
What is the average price of Nucleoside Analog Antiviral drugs?
The average NADAC for the Nucleoside Analog Antiviral class is $5.4118 per unit across 28 NDCs.
Which manufacturers make Nucleoside Analog Antiviral drugs?
14 manufacturers make drugs in the Nucleoside Analog Antiviral class. Ranked by number of NDCs, the largest are Aurobindo Pharma Limited (8), Major Pharmaceuticals (3), American Health Packaging (3), Ajanta Pharma USA Inc. (2), Camber Pharmaceuticals Inc. (2).
How has Nucleoside Analog Antiviral pricing changed recently?
Over the past 7 days, 8 NDCs in this class rose and 13 fell, with a class-wide average change of -1.3%.